Serial NT-proBNP assays could potentially identify which of those without clinical disease might most benefit from heart-failure preventive therapies, researchers propose.
The European Commission has expanded the indication of the SGLT2 inhibitor to include HF with mildly reduced and preserved ejection fraction, based on the DELIVER phase 3 trial.
Another SGLT2 inhibitor has been approved for type 2 diabetes based on results from 23 clinical trials that included 5000 patients and more than 300 patients who also had stage 3 chronic kidney disease.
Canada: The new use of sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with dipeptidyl peptidase 4 (DPP-4) inhibitors confers 20% lower dementia risk in older people with type 2 diabetes, a.
Observational data show that certain types of sulfonylureas for the treatment of type 2 diabetes are associated with more cardiovascular events compared to other types, such as glimepiride.